SCHEMBL761399

SCHEMBL761399

Cc1ccc2ccncc2c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.56
CYP1A2 P05177 4/20 0.56
PRKCZ Q05513 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
IMPDH2 P12268 2/20 0.47
MELK Q14680 1/20 0.44
ACHE P22303 1/20 0.44
F9 P00740 1/20 0.43
CYP19A1 P11511 1/20 0.42
TBXAS1 P24557 1/20 0.42
CCR1 P32246 1/20 0.41
CCR5 P51681 1/20 0.41
CCR8 P51685 1/20 0.41
ALDH1A1 P00352 2/20 0.41
NCK1 P16333 1/20 0.41
BACE1 P56817 1/20 0.41
IKBKB O14920 1/20 0.40
PRKCI P41743 1/20 0.39
TDO2 P48775 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30824503 1.00 CYP2A6 (0.56) CYP2A6CYP1A2PRKCZTDP1IMPDH2
SCHEMBL24621868 0.91 CYP2A6 (0.54) CYP2A6CYP1A2PRKCZTDP1IMPDH2
SCHEMBL13670757 0.91 CYP2A6 (0.54) CYP2A6CYP1A2PRKCZTDP1IMPDH2
SCHEMBL2616771 0.91 CYP2A6 (0.59) CYP2A6CYP1A2PRKCZTDP1IMPDH2
SCHEMBL30969150 0.91 CYP2A6 (0.59) CYP2A6CYP1A2PRKCZTDP1IMPDH2
SCHEMBL8338092 0.84 PRKCZ (0.68) CYP1A2PRKCZIMPDH2MELKF9
SCHEMBL23555378 0.84 PRKCZ (0.68) CYP1A2PRKCZIMPDH2MELKF9
SCHEMBL13615233 0.84 PRKCZ (0.53) CYP2A6CYP1A2PRKCZTDP1IMPDH2
SCHEMBL17666296 0.82 PRKCZ (0.51) CYP1A2PRKCZF9PRKCITDO2
SCHEMBL19321774 0.81 CYP1A2 (0.46) CYP2A6CYP1A2PRKCZTDP1IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1082 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114014858-A Process for preparing polysubstituted indolizine derivatives 淮阴师范学院 2022-02-08 CN claimed
CN-107973388-A A kind of particulate matter filler for being used to strengthen ultrasonic oxygen-enriching device 北京中科宇清环保有限公司 2018-05-01 CN claimed
CN-107792937-A A kind of ultrasound-enhanced oxygen-enriching device based on micro-nano attenuating fluid 北京中科宇清环保有限公司 2018-03-13 CN claimed
EP-2091929-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS The European Molecular Biology Laboratory (DE) 2009-08-26 EP claimed
US-20080194524-A1 Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof JERINI AG (DE) 2008-08-14 US claimed
WO-2007107352-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2007-09-27 WO claimed
EP-1703912-A1 COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF Jerini AG (DE) 2006-09-27 EP claimed
WO-2005063259-A1 COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2005-07-14 WO claimed
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2025-03-13 US disclosed
CN-119421877-A Substituted heterocyclic compounds as HSET inhibitors 默克专利股份公司 2025-02-11 CN disclosed
EP-4463444-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS Merck Patent GmbH (DE) 2024-11-20 EP disclosed
EP-3651762-B1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 UNIV VANDERBILT (US) 2024-07-03 EP disclosed
WO-2024108155-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-05-23 WO disclosed
WO-2024103126-A1 TSPO LIGANDS THE UNIVERSITY OF SYDNEY (AU) 2024-05-23 WO disclosed
EP-0920414-A1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA & UPJOHN S.p.A. (IT) 1999-06-09 EP disclosed
WO-1997049674-A1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA & UPJOHN S.P.A. (IT) 1997-12-31 WO disclosed
EP-0014929-B1 DIAGNOSTIC MEANS, PROCESS FOR ITS PREPARATION AND ITS USE IN DETERMINING LEUCOCYTES IN BODY FLUIDS Roche Diagnostics GmbH (DE) 1982-01-06 EP disclosed
US-4299917-A IMPREGNATION OF AN ABSORBENT CARRIER WITH A SULPHONPHTHALEIN ESTER AND AN ACTIVATOR BOEHRINGER MANNEHEIM GMBH (DE) 1981-11-10 US disclosed
EP-0014929-A1 Diagnostic means, process for its preparation and its use in determining leucocytes in body fluids Roche Diagnostics GmbH (DE) 1980-09-03 EP disclosed
US-4053318-A SENSITIZING MEROCYANINE DYE FUJI PHOTO FILM CO., LTD. (JA) 1977-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194524-A1 Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof CCNB1, CCNB2, CCNA1 CYP2A6 2487/4885CYP1A2 1399/4885PRKCZ 965/4885
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS VHL, CDKN1A, CCNI CYP2A6 3732/4885CYP1A2 2245/4885PRKCZ 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.